Acute Pain News and Research

RSS

P3 survey: 44% of U.S. patients receive inadequate relief of moderate-to-severe acute pain

A new survey shows almost half (44%) of U.S. patients in outpatient settings received potentially inadequate relief of moderate-to-severe acute pain.

15 Sep 2011

Chronic pain gene discovered

Scientists have found the gene responsible for chronic pain. It said that this could lead to drugs for treating long-lasting back pain.

12 Sep 2011

Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain

DURECT Corporation announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR known as BESST.

6 Sep 2011

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

A new meta-analysis published this week in Drugs in R&D, reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.

2 Sep 2011

$VP, balloon kyphoplasty safe and effective for women with vertebral fractures$

VP, balloon kyphoplasty safe and effective for women with vertebral fractures

A working group of the International Osteoporosis Foundation (IOF) has issued a literature review of prospective controlled studies comparing the efficacy and safety of two minimally invasive techniques for vertebral augmentation after spine fracture: vertebroplasty (VP) and balloon kyphoplasty.

2 Aug 2011

Pain intensity and location can predict chronic low back pain

By some estimates, up to 85 percent of Americans have experienced low back pain and research reported in The Journal of Pain showed that pain intensity ratings, pain location and sensory and affective variables differ among individuals with acute and chronic low back pain. In some cases, these factors might be predictive of which acute pain patients may develop chronic pain.

29 Jul 2011

QRxPharma raises A$25 million, announces A$10.4 million Rights Issue

QRxPharma Limited is pleased to announce the successful completion of a placement to institutions and professional investors raising A$25 million which was significantly oversubscribed. The Placement was very well supported by both existing and new investors including Australia, US and UK based fund managers.

25 Jul 2011

QRxPharma seeks NDA approval for MoxDuo IR

QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.

18 Jul 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society, www.ampainsoc.org, today honored the recipients of its fifth annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers.

21 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

12 May 2011

Pacira to present EXPAREL data in postsurgical pain at two medical meetings

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL™ will be presented at two medical meetings.

6 May 2011

Spanish tool measures infant pain rapidly and simply

It turns out to be difficult to find out exactly how much a child who cannot yet speak suffers after a surgical operation. Researchers at the University Hospital of La Paz, in Madrid, have validated the 'Llanto' scale, the first, and only, tool in Spanish which measures infant pain rapidly and simply.

20 Apr 2011

QRxPharma receives new U.S. Patent for MoxDuo IR in treatment of acute pain

QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

15 Apr 2011

Meditation can conquer pain: Well almost!

Meditation can be used as a powerful painkiller says new research published in the Journal of Neuroscience. The study from Wake Forest Baptist Medical Center showed as much reflected in perception of the participants as well as their brain scans.

7 Apr 2011

Higher prescribed doses associated with increased risk of opioid overdose death

In an analysis of opioid prescription patterns and deaths, receiving higher prescribed doses is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk, according to a study in the April 6 issue of JAMA.

6 Apr 2011

Patients prescribed high doses of pain medications at higher risk of overdose: Study

According to a study published in the April 6 issue of the Journal of the American Medical Association JAMA, receiving higher prescribed doses of opioid prescriptions is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk.

5 Apr 2011

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011